For investors Ready to Jump on The Hemp CBD Bandwagon: Link Reservations Inc (LRSV), Tilray Inc. (TLRY), CV Sciences, Inc. (CVSI)

High-flying and volatile cannabis stocks have caught the attention of both the Main street and Wall Street this year. For investors ready to jump on the hemp CBD bandwagon. Theses 3 cannabis/CBD companies should be highly considered this year as their shares saw an increase in momentum in recent months.

Link Reservations Inc (OTC: LRSV) is CBD Petcare provider dedicated to improving the health and life conditions of pets worldwide. Developing and marketing hemp-based CBD products for cats, dogs and horses, the Company is currently present in Europe and in the US. A pioneer in the area, Link Reservations Inc products can be found under its brand LinkResPets (www.linkrespet.com).

Two weeks after the company announced the acquisition of both the DailyLifeCBD, a website selling CBD products for people, and its existing product line, the company introduced CBD topical creamto its DailyLifeCBD product line. The new product, developed to soothe and relieve irritated and dry skin, will be sold through the Company’s DailyLifeCBD website, and be targeted to people, as opposed to pets.

Tilray Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, recently announced it has established an agreement with Grow Pharma to import and distribute Tilray’s medical cannabis products into the United Kingdom (UK). This agreement allows Tilray to provide authorized UK patients in need with a locally maintained supply of medical cannabis solutions.

Tilray expects to have a range of GMP-certified, medical cannabis products available for patients in the UK by March 2021. Patients looking to use medical cannabis will have access to Tilray products in the UK by obtaining prescriptions through private practice or the National Health Service (NHS).

CV Sciences, Inc. (OTCQB: CVSI), a preeminent leader in hemp derived cannabidiol (CBD) products, recently announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners.

Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review.

Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.

Comments

LEAVE A REPLY

Please enter your comment!
Please enter your name here

FEATURED

Advertisment